
Cutting animal testing will jeopardize human health
This change follows the FDA's plan to phase out the requirement for animal testing of drugs, which marked the beginning of an overall shift away from animal research to what the new leadership refers to as 'more effective, human-relevant methods.'
What this means is the FDA intends to allow new drugs to be trialed in people without prior animal tests, and that the NIH will restrict funding for the very kind of research that has led to transformative medical discoveries.
As a biomedical researcher using mouse models and other tools to better understand and treat human disease, I am deeply concerned. Eliminating animal testing will make our drug supply less safe and set us back decades in making groundbreaking biomedical discoveries.
Let's look first at drug regulation. Identifying potential new therapies first depends heavily on knowledge gained from preclinical studies in animals. These studies form the basis of biological discovery, including assessing a drug's relevance, safety and potential efficacy before it's ever given to humans.
Without this critical step, discovering new drugs will be far more difficult to begin with and their effects far less predictable. Only after these initial studies do drugs move into clinical testing — involving progressively larger human cohorts across three phases before approval.
Animal models are a crucial component of biomedical research because they allow us to test unpredictable biological effects between different organs and systems within a living body.
For example, a cancer drug might successfully kill tumor cells in a dish, but in a whole organism, it could cause unexpected heart damage or trigger a harmful immune response affecting other organs. An animal test is the closest possible test of the utility and safety of any drug before it's given to humans. If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ever tested in will be a human body.
Researchers also use animals to understand diseases and develop completely new therapies. Laboratory mice, the most commonly used animal model, have been likened to the Rosetta Stone of immunology. Much of what we now know about the immune system has been deciphered through them.
Think of immunotherapies for cancer, immunosuppressive drugs for autoimmune conditions, or treatments for allergies and infectious diseases. None of these life-saving medicines would exist today without decades of foundational research in animal models.
Nearly half of NIH-funded grants involve animal use. So why would the world's largest public funder of biomedical research decide to make such drastic changes? The argument is that new human-based approaches can serve as a better alternative. These include lab-grown human models, computational tools and other approaches. And these can certainly complement animal models, as my colleagues and I have long worked toward. But it is premature to treat them as viable replacements.
One of the main criticisms of animal research is that the findings don't always translate directly to humans. That is true, but there's little evidence that the proposed alternatives yield more reliable or predictive results.
Instead of abandoning animal research, we should focus on improving existing models to better reflect human biology.
And it's true that some mice need improving. For example, in 2006, a new drug that acts on immune cells passed through animal testing and reached the human clinical trial phase, yet it left six healthy volunteers in a critical condition.
Researchers later realized that laboratory mice had less activated immune systems compared with adult humans, because the abnormally hygienic environment of the lab prevented proper immune growth. (Germs are actually essential in teaching the immune system how to protect us.)
Researchers confirmed that adding mice from a pet-store (living under less sterile and more natural conditions with diverse germs) to the same cages as laboratory mice helped the latter's immune systems more closely resemble those of humans.
When researchers tested the same drug from the 2006 trial in mice with more natural immune systems, they found that the mice experienced similar inflammatory complications. More recently, researchers using such mice were also able to better understand the causes of side effects from cancer immunotherapies.
And work has been under way using these improved mice for many other studies that can advance human health.
This discovery helped launch a whole new field, in which researchers like myself are working to improve mouse models and accelerate biomedical discoveries.
After the announcement, the People for the Ethical Treatment of Animals called it a 'groundbreaking move' that is 'a crucial first step to modernizing science and sparing millions of animals from miserable lives and deaths in laboratories.'
But it's possible to care for animals ethically without eliminating their scientific use. Indeed, the NIH has had animal welfare policies dating back to the beginning of the 1900s.
And for at least a decade, all grant proposals have had to include consideration of alternative approaches, scientific justification of animal use and detailed protocols to minimize their distress. Institutions' protocols are also regularly reviewed for accreditation.
We still need animal testing to find new treatments. Take the story of one-week-old baby KJ that was in the news in May. KJ was born with a severe genetic disorder that kills nearly half of affected babies in early life. But, through extensive medical efforts, which included the use of a mouse model modified with the diseased gene portion specific to KJ, a customized therapy was developed and successfully administered within eight months.
The list of biomedical successes that used animal models spans centuries — from first defining the functions of the brain and heart, to the discovery of insulin, to the development of 'miracle' cancer drugs.
Human health is a shared priority, and now more than ever, it demands meaningful collaboration between scientists and physicians, policymakers and the public to protect the research systems that have enabled medicine's greatest breakthroughs.
To borrow the recent words of Nobel laureate Ardem Patapoutian, 'Now is the time for all of us to speak up — because protecting American science means protecting our future shared prosperity.'
The FDA and NIH are welcoming public feedback on this and likely future workshops, and I urge everyone to make their voices heard.
Anis Barmada is a biomedical researcher at Yale School of Medicine, P.D. Soros Fellow, and Public Voices Fellow of The OpEd Project. His research combines animal models with human-based and computational tools to better understand and treat human disease.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UMass Amherst marmoset monkey lab that drew PETA's ire closes
AMHERST — A researcher whose controversial use of marmoset monkeys to unlock the secrets of Alzheimer's, aging and women's health drew the fury of PETA has closed her lab at the University of Massachusetts Amherst. In a message posted to her own website, Agnès Lacreuse says caring for primates requires top-quality infrastructure and resources. She is grateful to the National Institutes of Health and others for more than $6 million in federal funding. 'However, current efforts to destroy science and slash research funding undermine my ability to continue support for nonhuman primate research at UMass,' she said. The lab is finishing up a research project concerning the topic of breast cancer. 'Above all, my heart goes out to each one of the beloved monkeys who helped advance scientific knowledge and improve the lives of humans and other animals,' she said. The University of Massachusetts released a written statement: 'The lab, whose work has been dedicated to studies that advance the knowledge of the aging process with a focus on Alzheimer's disease and women's health (including breast cancer treatments), recently completed NIH grant-funded research using non-human primates. The funded experiments ended as planned, within the scheduled end of the grant.' PETA, People for the Ethical Treatment of Animals, declared victory in a news release. 'We were determined to close this laboratory and end the torture of these tiny monkeys, and we did,' says PETA Senior Vice President Kathy Guillermo. 'Lacreuse's reign of terror is over.' PETA described how Lacreuse's laboratory staff drilled holes in marmosets' skulls to implant electrodes, cut into their necks and threaded wires through their bodies. Stories by Jim Kinney Sports betting brought trouble for gamblers, not jobs for Mass., UMass research finds After word of potential Mercy sale, Baystate CEO reassures staff but points to nondisclosure, confidentiality Pridelands on Main St., outdoor beer garden funded through ARPA, drawing crowds Read the original article on MassLive. Solve the daily Crossword


Business Wire
an hour ago
- Business Wire
Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Breyanzi ® (lisocabtagene maraleucel; liso-cel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 5, 2025. BMY announces an FDA acceptance of the regulatory filing with priority review for their personalized treatment option for adult patients with relapsed or refractory marginal zone lymphoma #MZL Share 'While initial therapy for MZL can be effective, multiple relapses over the course of several years are common, leaving patients in need of a new treatment option that can provide high, lasting response rates,' said Rosanna Ricafort, vice president, Senior Global Program Lead for Hematology and Cell Therapy, Bristol Myers Squibb. 'This FDA acceptance brings us one step closer to potentially standardizing CAR T cell therapy as a treatment option for MZL, while building on our commitment to bring this personalized therapy to as many eligible patients as possible.' The application is based on results from the primary analysis of the MZL cohort in TRANSCEND FL, an open-label, multicenter, Phase 2, single-arm study, which was shared in an oral presentation during the 2025 International Conference on Malignant Lymphoma (ICML) in June 2025. The development progress of Breyanzi reflects BMS' continued efforts to collaborate across the healthcare ecosystem, with the ultimate goal of reaching more patients and democratizing access to cell therapy. Recently, the FDA approved streamlined patient monitoring requirements and the removal of the REMS program for Breyanzi, easing known barriers to treatment and administration while maintaining patient safety. About TRANSCEND FL TRANSCEND FL (NCT04245839) is an open-label, global, multicenter, Phase 2, single-arm study to determine the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma. The primary outcome measure is overall response rate. Secondary outcome measures include complete response rate, duration of response, and progression-free survival. About MZL Marginal zone lymphoma (MZL) is the third most common lymphoma, accounting for about 7% of all non-Hodgkin lymphoma cases. Most patients with MZL are at a median age of 67 years when they are diagnosed. MZL develops when white blood cells cluster together to form lumps in a person's lymph nodes or organs. Initial therapy often leads to remission, but relapse is common, sometimes occurring several times over many years. A small portion of MZL cases transform into diffuse large-B-cell lymphoma, a more aggressive lymphoma. About Breyanzi Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. Breyanzi is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment. The treatment process includes blood collection, CAR T-cell creation, potential bridging therapy, lymphodepletion, administration, and side-effect monitoring. Breyanzi is approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior line of therapy, has received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of therapy and relapsed or refractory follicular lymphoma (FL) in the third-line plus setting, and is approved for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in the third-line plus setting. Breyanzi is also approved in Japan, the European Union (EU), Switzerland, the United Kingdom, and Canada for the treatment of relapsed or refractory LBCL after at least one prior line of therapy; in Japan for the treatment of patients with relapsed or refractory high-risk FL after one prior line of systemic therapy, and in patients with relapsed or refractory FL after two or more lines of systemic therapy; and in the EU for the treatment of relapsed or refractory FL after two or more lines of systemic therapy. Bristol Myers Squibb's clinical development program for Breyanzi includes clinical studies in several types of lymphoma. For more information, visit Breyanzi U.S. FDA-Approved Indications BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or relapsed or refractory disease after two or more lines of systemic therapy. Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma. adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Breyanzi U.S. Important Safety Information WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids. Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Cytokine Release Syndrome Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 702 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 54% of patients, including ≥ Grade 3 CRS in 3.2% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 98% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (≥10%) were fever, hypotension, tachycardia, chills, hypoxia, and headache. Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI. Neurologic Toxicities Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred. In clinical trials of BREYANZI, CAR T cell-associated neurologic toxicities occurred in 31% of patients, including ≥ Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7 days (range: 1 to 119 days). Of patients developing neurotoxicity, 82% also developed CRS. The most common neurologic toxicities (≥5%) included encephalopathy, tremor, aphasia, headache, dizziness, and delirium. CRS and Neurologic Toxicities Monitoring Monitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time. Hypersensitivity Reactions Allergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO). Serious Infections Severe infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 34% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.7%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI. Febrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad- spectrum antibiotics, fluids, and other supportive care as medically indicated. Monitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections. Viral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines. Prolonged Cytopenias Patients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration. Hypogammaglobulinemia B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 10% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated. Live vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI. Secondary Malignancies Patients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. Three of 89 (3%) safety evaluable patients with R/R CLL/SLL developed IEC-HS. Time to onset of IEC-HS ranged from 7 to 18 days. Two of the 3 patients developed IEC-HS in the setting of ongoing CRS and 1 in the setting of ongoing neurotoxicity. IEC-HS was fatal in 2 of 3 patients. One patient had fatal IEC-HS and one had ongoing IEC-HS at time of death. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines. Adverse Reactions The most common adverse reaction(s) (incidence ≥30%) in: LBCL are fever, cytokine release syndrome, fatigue, musculoskeletal pain, and nausea. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, platelet count decrease, and hemoglobin decrease. CLL/SLL are cytokine release syndrome, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, and diarrhea. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, hemoglobin decrease, platelet count decrease, and lymphocyte count decrease. FL is cytokine release syndrome. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease. MCL are cytokine release syndrome, fatigue, musculoskeletal pain, and encephalopathy. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, and platelet count decrease. Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide. Bristol Myers Squibb: Unlocking the Full Potential of Cell Therapy A pioneer in harnessing the immune system to fight cancer and an established leader in cell therapy, Bristol Myers Squibb is uniquely positioned to unlock the full potential of this technology across blood cancers and within new frontiers, including autoimmune disease. Bristol Myers Squibb is currently the only company with two approved CAR T cell therapies with two distinct targets, available in major markets around the world. Our bold vision for the future is one in which hundreds of thousands of patients can be treated with cell therapy's transformational potential. The building blocks to realize this ambition—a promising and differentiated pipeline, extensive translational and clinical data sets, a deep bench of talent, and robust manufacturing capabilities—are in our cells. We are laser-focused on advancing the field of cell therapy toward a true revolution for patients. Learn more about the science behind cell therapy and ongoing progress at Bristol Myers Squibb here. Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that Breyanzi (lisocabtagene maraleucel) may not receive regulatory approval for the additional indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether Breyanzi for such indication will be commercially successful. No forward-looking statement can be guaranteed. It should also be noted that acceptance of the sBLA does not change the standards for FDA approval. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.


Business Upturn
3 hours ago
- Business Upturn
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
By GlobeNewswire Published on August 4, 2025, 23:31 IST PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to FDA and to be conducted by Immuthera has been received favorably, may include Polish patients in the U.S. Statistical analysis, and could be treated as pivotal. The project has received an $11.3 million non-dilutive grant from the Polish Medical Research Agency. PolTREG is developing Multi-edited, Allogeneic CAR-Tregulatory cell therapies which can be used to treat patients diagnosed with T1D (Stage 3), which, in combination with PTG-007 in Stage 1 and Stage 2, will provide clinical solutions for patients across all Stages of T1D. 4 August 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies for autoimmune diseases, and its U.S. subsidiary Immuthera, announced that they have administered the first dose of PTG-007 to a patient in their Phase II clinical trial for pre-symptomatic type 1 diabetes. The trial, called 'Pre-Treg' will enroll up to 150 genetically high-risk children and adolescents (aged 3–18) who have not yet developed clinical symptoms of the disease. If successful, PolTREG aims to develop and register the world's first therapy to prevent the onset of type 1 diabetes symptoms. The company has proposed a parallel study to Pre-Treg to the U.S. Food and Drug Administration (FDA) in a recent Pre-IND meeting. The FDA's response was that the U.S. Trial could potentially be registrational. Further, patients enrolled in Poland at Stage 1 of the disease may, upon completion of enrollment, be included in the U.S. statistical analysis of the study. 'Long-term data from our clinical program of PTG-007 in symptomatic type 1 diabetes confirm both the safety and efficacy of the therapy. Modern medicine is increasingly focusing on interventions applied earlier or even before the first clinical symptoms appear. Our therapy fits perfectly into this paradigm. By administering it at the earliest stage of disease development, we anticipate highly promising outcomes—possibly even halting disease progression before clinical symptoms emerge. If the trial confirms the therapy's efficacy, we have the opportunity to develop and register the world's first drug to prevent the clinical onset of type 1 diabetes. We believe this therapy holds significant market and partnership potential' – said Prof. Piotr Trzonkowski, CEO and Co-Founder of PolTREG S.A. The Phase II study will include 150 participants in a randomized, placebo-controlled design. Recruitment is ongoing at three academic centers in Poland, with six additional clinical hospitals set to begin enrollment shortly. PolTREG has been awarded a non-dilutive grant of PLN 31.7 million (approx. $11.3 million) from the Polish Medical Research Agency to support the execution of this Phase II trial. PreTreg is one of PolTREG's flagship programs. In type 1 diabetes, the autoimmune destruction of insulin-producing pancreatic islets underscores the importance of early intervention. In the pre-symptomatic phase, a sufficient number of islets remain to maintain normal glucose regulation, and the autoimmune process is still limited and more readily controllable. Preventive therapy at this stage could halt the autoimmune attack, leaving patients genetically predisposed but clinically healthy for life. Upon successful completion of this trial and confirmation of safety and efficacy, PolTREG could establish the first approved drug to prevent symptomatic type 1 diabetes. Type 1 diabetes progresses through three stages. Stages 1 and 2 is considered presymptomatic and occurs in young children, typically 3 years old or older. Because these patients are not yet sick, safety is the highest priority. PTG-007's 12 year safety data makes it an ideal treatment for this age group and this stage of disease. Diagnosis of Type 1 Diabetes occurs in Stage 3 when symptoms occur which can lead to potentially life threatening complications such as diabetic ketoacidocis, heart and blood vessel disease, nerve damage, eye damage, kidney disease, and foot damage. These patients are typically older and require supplemental insulin. Due to the complications in Stage 3, more aggressive treatments are warranted. PolTREG and Immuthera are developing Tregulatory cell therapies that have clinically derived edits to improve function, modifications to make them 'off-the-shelf' (allogeneic), and a Chimeric Antigen Receptor to improve targeting of the disease causing cells that drive the autoimmune response. Taken together, PolTREG and Immuthera have a pipeline of Tregulatory cell therapies that will cover the full spectrum of presymptomatic and symptomatic Type 1 Diabetes. PolTREG is also expanding its U.S. presence. In mid-June, the company established its wholly owned U.S. subsidiary, Immuthera, registered as a Delaware C Corporation. In recent weeks, prominent experts in diabetes and neuroimmunology—Prof. Jay Skyler, Prof. Desmond Schatz, and Prof. Lawrence Steinman—joined the company's Scientific Advisory Board. In late July, PolTREG received the formal outcome of its pre-IND meeting with the FDA and is now preparing its IND submission. The company has partnered with Noble Capital Markets, Inc. and Kinexum Services LLC to support its U.S. regulatory strategy, and is collaborating with Swiss-based Antion Biosciences to develop next-generation allogeneic Treg therapies. About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For further information please contact: PolTREG Piotr TrzonkowskiChief Executive Officer [email protected] +48 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.